Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Merck USA (MSD) acquires Phase 2 biotech for US$ 10.8 Bln.

<< Previous

Bullboard Posts

Next >>

Comment by KTDfyion Apr 16, 2023 3:35pm

170 Views

Post# 35397499

RE:RE:RE:RE:RE:RE:Merck USA (MSD) acquires Phase 2 biotech for US$ 10.8 Bln.

Coffey did mention a reference to another drug that failed in its purpose, yet became very profitable, that being Viagra. I've thought, because they can determine at 2 to 3 weeks if therapy is working. It could be used for just that alone. I think that's what you were trying to say anyway. Just thinking about this. A few doses of pelareorep and the Dr the patient know if the current therapy is working. A valuable tool in figuring out the TME, No guessing. Just saying there is value in that alone.

<< Previous

Bullboard Posts

Next >>

How one company is disrupting PoC testing